Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Transplant Surgery

Symptoms & Diagnostic Challenges: The Great Mimicker

At a Glance

Post-transplant lymphoproliferative disease (PTLD) is difficult to diagnose because its symptoms—like fever, fatigue, and organ dysfunction—often mimic infections or transplant rejection. A tissue biopsy is the only definitive way to confirm PTLD, even if EBV blood tests are negative.

Identifying PTLD can be an incredibly frustrating process because it is a “great mimicker.” Its symptoms often look exactly like common post-transplant complications, such as an infection or even the body’s attempt to reject the new organ [1][2].

Common Symptoms: Vague and Specific

PTLD does not have a single “classic” look. Instead, it presents in two main ways: general “B-symptoms” and site-specific symptoms [3].

General “B-Symptoms”

These are whole-body symptoms that can feel like a lingering flu [3]. If you or your child experience any of these symptoms, contact your transplant team immediately—do not wait for your next scheduled appointment.

  • Fever and Night Sweats: Persistent, unexplained fevers or waking up drenched in sweat [1].
  • Weight Loss: Losing weight without trying [3].
  • Fatigue: Deep, overwhelming exhaustion that doesn’t improve with rest [3].

Site-Specific Symptoms

Often, PTLD grows in a specific part of the body, causing symptoms related to that area [3]:

  • The Transplanted Organ (Allograft): You may experience pain, tenderness, or a decline in organ function (e.g., rising creatinine in a kidney transplant) [4][5].
  • Gastrointestinal (GI) Tract: Abdominal pain, nausea, vomiting, or even bleeding [6].
  • Central Nervous System (CNS): New headaches, seizures, confusion, or trouble walking [7][8].
  • Lymph Nodes: Swollen, painless “lumps” in the neck, armpits, or groin [9].

The Diagnostic “Triple Threat”

Doctors often struggle to diagnose PTLD quickly because it is frequently confused with three other conditions [1][10]:

  1. Acute Cellular Rejection (ACR): The most common pitfall. Both PTLD and rejection can cause fever and organ failure. In fact, PTLD and rejection can sometimes happen at the same time in the same organ [11].
  2. Opportunistic Infections: Common viruses like CMV (Cytomegalovirus) cause nearly identical symptoms to PTLD [2].
  3. Inflammation: General inflammation or other autoimmune issues can mimic the “hot spots” seen on imaging [12].

Why Blood Tests Aren’t Always Enough

A common misconception is that if the EBV viral load in your blood is low or negative, you don’t have PTLD. This is not always true [9].

  • Localized Disease: Sometimes the PTLD is tucked away in one specific organ or the brain, and the virus hasn’t spilled over into the bloodstream in large amounts [9][13].
  • EBV-Negative PTLD: About 20–30% of PTLD cases are “EBV-negative,” meaning the virus isn’t the main driver. In these cases, the blood test will always be negative [14][15].

Because of this, a tissue biopsy remains the only definitive way to confirm PTLD [9].

The Role of PET/CT Scans

A PET/CT scan is a powerful tool used to find PTLD throughout the body [16]. It uses a radioactive sugar “tracer” to find areas of high activity (hot spots) [17].

  • The Benefit: It helps doctors see the full “burden” of the disease and tells them the best place to perform a biopsy [18][17].
  • The Limitation: PET scans are sensitive but not specific. This means they are great at finding something wrong, but they can’t tell the difference between PTLD, a simple infection (like TB or pneumonia), or post-surgical inflammation [12][19].

Early-Onset vs. Late-Onset

The timing of your symptoms matters. Early-onset PTLD (usually within the first year) is almost always linked to EBV and often involves the transplanted organ [20][21]. Late-onset PTLD (occurring years later) is more likely to be EBV-negative and behaves more like a traditional lymphoma [22][23]. Regular, lifelong monitoring is essential because the risk never fully disappears [24][25].

Common questions in this guide

Why is PTLD hard to diagnose?
PTLD is often called a 'great mimicker' because its symptoms closely resemble common post-transplant complications. It can look exactly like an opportunistic infection or your body rejecting the new organ, making standard tests harder to interpret.
Does a negative EBV blood test mean I don't have PTLD?
No, a low or negative Epstein-Barr Virus (EBV) test does not completely rule out PTLD. Sometimes the disease is localized in a specific organ without spilling into the blood, or it may be an EBV-negative form of PTLD.
What are the 'B-symptoms' of PTLD?
General B-symptoms affect the whole body and can feel like a severe, lingering flu. They include persistent fevers, waking up drenched in sweat (night sweats), unintended weight loss, and overwhelming fatigue that does not improve with rest.
Can I have PTLD and organ rejection at the same time?
Yes, it is possible to experience both PTLD and acute cellular rejection simultaneously in the same transplanted organ. Since both can cause fever and organ dysfunction, your doctor will likely need a tissue biopsy to determine exactly what is happening.
Why do doctors use a PET scan if it can't definitively diagnose PTLD?
A PET/CT scan is highly sensitive and helps doctors locate areas of high cellular activity throughout the body. While it cannot distinguish between PTLD, an infection, or inflammation, it shows the full extent of the issue and pinpoints the best location to perform a biopsy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Could my symptoms (fever, weight loss, or specific organ pain) be related to PTLD rather than just a common infection or rejection?
  2. 2.If my blood EBV viral load is low or negative, does that completely rule out PTLD, or should we still consider a biopsy?
  3. 3.How can you be sure my graft issues are rejection and not PTLD, given that they can look similar on standard tests?
  4. 4.Is it possible that I have both PTLD and rejection occurring at the same time?
  5. 5.If the PET/CT shows 'hot spots,' what else besides PTLD could be causing that (like an infection or inflammation)?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (25)
  1. 1

    Posttransplant Lymphoproliferative Disorder Status Post-Solid Organ Transplant Presenting to the Emergency Department: Single Institute Experience.

    Rao S, Smith DA, Kikano EG, et al.

    Journal of computer assisted tomography 2021; (45(6)):894-903 doi:10.1097/RCT.0000000000001212.

    PMID: 34347710
  2. 2

    Clinical analysis of malignant lymphoma secondary to transplantation: the notorious lymphoproliferative disease.

    Yan Z, Wang H, Liu Y, et al.

    American journal of translational research 2023; (15(11)):6632-6643.

    PMID: 38074803
  3. 3

    COVID-19 and Superimposed Aspergillosis in a Dual Organ Recipient with Diagnosed B-Cell Lymphoproliferative Disorder: A Rare Case Report and Literature Review.

    Karadžić-Ristanović V, Pavlović J, Brković V, et al.

    Diseases (Basel, Switzerland) 2025; (13(10)) doi:10.3390/diseases13100339.

    PMID: 41149073
  4. 4

    Intussusception Can Be the First Sign of Post-transplant Lymphoproliferative Disease.

    Atici SD, Arican C, Avci EK, et al.

    Transplantation proceedings 2019; (51(4)):1184-1186 doi:10.1016/j.transproceed.2019.01.085.

    PMID: 31101196
  5. 5

    [Primary central nervous system post-transplant lymphoproliferative disorder with few specific abnormal findings observed on MRI and in the cerebrospinal fluid].

    Takeuchi Y, Ochiai J, Onoda O, et al.

    Rinsho shinkeigaku = Clinical neurology 2022; (62(1)):44-48 doi:10.5692/clinicalneurol.cn-001677.

    PMID: 34924473
  6. 6

    [A case of primary central nervous system post-transplant lymphoproliferative disease 14 years after living donor liver transplantation].

    Otsuka H, Shima T, Yoshida K, et al.

    Rinsho shinkeigaku = Clinical neurology 2024; (64(11)):794-801 doi:10.5692/clinicalneurol.cn-001991.

    PMID: 39428512
  7. 7

    Primary central nervous system post-transplantation lymphoproliferative disorder: A case report and systematic review of imaging findings.

    Hoyt D, Hughes J, Liu J, Ayyad H

    Radiology case reports 2024; (19(6)):2168-2182 doi:10.1016/j.radcr.2024.02.030.

    PMID: 38515768
  8. 8

    Primary Central Nervous System Posttransplant Lymphoproliferative Disorder After Kidney Transplant.

    Stone T, Eskandari R, Baker T, et al.

    Journal of pediatric hematology/oncology 2021; (43(4)):144-146 doi:10.1097/MPH.0000000000001818.

    PMID: 32398602
  9. 9

    Central nervous system post-transplant lymphoproliferative disorder after allogeneic hematopoietic stem cell transplantation: The Nagasaki transplant group experience.

    Sakamoto H, Itonaga H, Taguchi J, et al.

    Leukemia research reports 2019; (11()):27-30 doi:10.1016/j.lrr.2019.04.003.

    PMID: 31049285
  10. 10

    Characterization and outcome of post-transplant lymphoproliferative disorders within a collaborative study.

    Lückemeier P, Radujkovic A, Holtick U, et al.

    Frontiers in oncology 2023; (13()):1208028 doi:10.3389/fonc.2023.1208028.

    PMID: 37427100
  11. 11

    Simultaneous Presentation of Post-Transplant Lymphoproliferative Disorder (PTLD) and Acute Cellular Rejection (ACR) in a Liver Transplant Recipient: A Therapeutic Conundrum.

    Mishra A, Kubina M, Peddu DK, et al.

    Case reports in gastrointestinal medicine 2025; (2025()):1627234 doi:10.1155/crgm/1627234.

    PMID: 41200208
  12. 12

    Extrapulmonary Tuberculosis Mimicking Malignancy.

    Güneren C, Uslu Beşli RL, Sayman HB

    Molecular imaging and radionuclide therapy 2025; doi:10.4274/mirt.galenos.2025.43925.

    PMID: 41414703
  13. 13

    Epstein Barr Virus Quantitative Polymerase Chain Reaction Monitoring in Lung and Bone Marrow Transplant Patients to Predict Post-Transplant Lymphoproliferative Disorder: A Systematic Review.

    Divithotawela C, Lee SZ, Schulz M, Chambers DC

    Transplantation proceedings 2025; (57(5)):931-939 doi:10.1016/j.transproceed.2025.03.008.

    PMID: 40316451
  14. 14

    A Case of Epstein-Barr Virus-Negative Post-transplant Lymphoproliferative Disorder in a Solid Organ Transplant Recipient With Untreated Chronic Hepatitis C.

    Asiimwe E, Mead M

    Cureus 2024; (16(1)):e53323 doi:10.7759/cureus.53323.

    PMID: 38435861
  15. 15

    Epstein-Barr Virus-Negative Diffuse Large B-Cell Post-transplant Lymphoma in an Epstein-Barr Virus-Positive Recipient.

    Lee C, Vincentelli H, Visuri J, et al.

    Cureus 2021; (13(9)):e18134 doi:10.7759/cureus.18134.

    PMID: 34567913
  16. 16

    18F-FDG PET/CT is an ideal imaging modality for the early diagnosis of relapsing polychondritis: A case report.

    Wang J, Liu X, Pu C, Chen Y

    Medicine 2017; (96(30)):e7503 doi:10.1097/MD.0000000000007503.

    PMID: 28746194
  17. 17

    18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Scan in an Unusual Case of Lymphoma with Secondary Involvement of Uterine Cervix Presenting as a Pathological Fracture.

    Sasikumar A, Joy A, Pillai MR, Thomas B

    Indian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India 2017; (32(1)):54-56 doi:10.4103/0972-3919.198483.

    PMID: 28242988
  18. 18

    FDG-PET/CT and Auricular Cartilage Biopsy Are Useful for Diagnosing with Relapsing Polychondritis in Patients without Auricular Symptoms.

    Okuda S, Hirooka Y, Itami T, et al.

    Life (Basel, Switzerland) 2021; (11(9)) doi:10.3390/life11090956.

    PMID: 34575105
  19. 19

    18F-fluorodeoxyglucose positron emission tomography/computed tomography in the diagnosis of benign pulmonary lesions in sarcoidosis.

    Zhao M, Xin XF, Hu H, et al.

    Translational lung cancer research 2019; (8(3)):208-213 doi:10.21037/tlcr.2019.06.09.

    PMID: 31367534
  20. 20

    The promise of a prophylactic Epstein-Barr virus vaccine.

    Balfour HH, Schmeling DO, Grimm-Geris JM

    Pediatric research 2020; (87(2)):345-352 doi:10.1038/s41390-019-0591-5.

    PMID: 31641280
  21. 21

    Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study.

    Walti LN, Mugglin C, Sidler D, et al.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2021; (21(7)):2532-2542 doi:10.1111/ajt.16423.

    PMID: 33289340
  22. 22

    Subtype-specific progression of post-transplant lymphoproliferative disease (PTLD) in children: Implications for age-based surveillance and early intervention strategies.

    Wang S, Zong Z, Li L, et al.

    Transplant immunology 2025; (93()):102321 doi:10.1016/j.trim.2025.102321.

    PMID: 41167402
  23. 23

    T-Cell Posttransplant Lymphoproliferative Disorders After Allogeneic Hematopoietic Stem Cell Transplantation: Case Series and Systemic Review.

    Jiang C, Huang J, Shao J, et al.

    Cell transplantation 2024; (33()):9636897241259722 doi:10.1177/09636897241259722.

    PMID: 38856035
  24. 24

    Post-Transplant Lymphoproliferative Disorder in Kidney Transplant Recipients: A Single-Center Experience in Japan.

    Ishihara H, Shimizu T, Unagami K, et al.

    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2016; (20(2)):165-73 doi:10.1111/1744-9987.12392.

    PMID: 26948427
  25. 25

    Clinical characteristics and outcomes of PTLD following intestinal transplantation.

    Wozniak LJ, Mauer TL, Venick RS, et al.

    Clinical transplantation 2018; (32(8)):e13313 doi:10.1111/ctr.13313.

    PMID: 29888807

This page provides educational information about PTLD symptoms and diagnostic challenges. Always consult your transplant team to evaluate any new symptoms or medical concerns.

Get notified when new evidence is published on Post-transplant lymphoproliferative disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.